icobrain aria (ARIA Detection)
Detect, measure and grade amyloid-related imaging abnormalities
Software · Cloud SaaSCompany source
Company profile
About Icometrix
Icometrix is a global leader in AI-driven neuroimaging solutions that transform how clinicians diagnose and monitor neurological disorders. The company's flagship icobrain platform uses artificial intelligence to automatically analyze brain MRI scans, detecting and quantifying subtle changes in brain structures and lesions over time. This longitudinal monitoring capability is crucial for timely diagnoses and therapeutic decisions across multiple neurological conditions. Icometrix offers disease-specific solutions for multiple sclerosis, dementia and Alzheimer's disease, amyloid-related imaging abnormalities (ARIA), traumatic brain injury, epilepsy, Parkinson's disease, stroke, and brain tumors. The platform assists radiologists and neurologists by comparing and quantifying brain MRI scans, making complex imaging data more actionable. With 9 FDA-cleared and CE-marked solutions, icometrix is recognized as the #1 validated AI solution for multiple sclerosis. The company's technology has been validated through over 270 scientific publications and is used across 30+ countries by 400+ healthcare institutions, enhancing care for over 7,000 patients. Clinical evidence demonstrates significant improvements in clinical workflows, including 150% increased detection of disease activity in MS, 40% faster radiological reading speed, and 2.5x faster detection of treatment failure. In 2024, GE HealthCare announced its intent to acquire icometrix to strengthen its neurology portfolio with advanced brain MRI assessment solutions. The company is headquartered in Leuven, Belgium, and continues to set the global standard in brain imaging AI through its commitment to precision and personalized medicine in neurology.
Company description Icometrix official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Icometrix?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's disease
- Amyloid-related imaging abnormalities (ARIA)
- Brain tumors
- Dementia
- Epilepsy
- Multiple Sclerosis
- Parkinson's disease
- Stroke
- Traumatic brain injury
Who it serves
- Health Systems
- Hospitals
- Neurology clinics
- Radiology practices
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
Markets30+ countries globally · Belgium · United States
Company sourceOfficial website
Company milestones
Platform expansion
GE HealthCare announced intent to acquire icometrix in 2024. MSAA and icometrix partnership announced June 2026 to expand MRI Access Program. Participation in RECLAIM observational study across European institutions. CPT-III codes 0865T/0866T now active and processed by over 30 insurers in U.S.
Partnerships
Recorded partners
- American Society of Neuroimaging
- European partner institutions in RECLAIM study
- GE HealthCare (acquirer)
- Multiple Sclerosis Association of America (MSAA)
- Shields Healthcare
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
icobrain dm (Dementia and Alzheimer's)
Supporting differential diagnosis and monitoring of atrophy in dementia
Software · Cloud SaaSCompany source
icobrain ep (Epilepsy)
Supporting differential diagnosis of epilepsy through abnormality patterns
Software · Cloud SaaSCompany source
icobrain ms (Multiple Sclerosis)
Accurately visualize lesion and brain volume changes over time in multiple sclerosis
Software · Cloud SaaSCompany source
icobrain pd (Parkinson's Disease)
Quantifies volumes of basal ganglia, brainstem, cerebellum, cortex, and ventricles
Software · Cloud SaaSCompany source
icobrain stroke
Measure stroke lesion volumes and perfusion abnormalities
Software · Cloud SaaSCompany source
icobrain tbi (Traumatic Brain Injury)
Quantify traumatic brain injury and track structural changes
Software · Cloud SaaSCompany source
icobrain tumor
Track changes in tumor resection cavity, core, and edema
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Lecanemab in practice: AI-derived MRI predictors of benefit and Amyloid Related Imaging Abnormalities (ARIA).Alzheimer's research & therapy · Jun 29, 2026
Spinal cord reserve is associated with multi-dimensional clinical resilience in multiple sclerosis.Journal of neurology · Jun 17, 2026
The relationship between objective and subjective cognitive performance and clinical and MRI disease burden in early multiple sclerosis.Scientific reports · May 16, 2026
The Ischemic Stroke Lesion Segmentation Challenge (ISLES)'24 Dataset: A Multimodal Stroke Imaging Dataset with Hyperacute CT, Acute Postinterventional MRI, and 3-month Clinical Outcomes.Radiology. Artificial intelligence · May 1, 2026
Cross-sectional brain volumetric measures and disability outcomes in relapsing-remitting multiple sclerosis.Journal of neurology · Apr 1, 2026
Incorporating Measures of Cognitive Processing Speed and Brain Volume in Clinical Management of Pediatric Onset Multiple Sclerosis.Pediatric neurology · Feb 1, 2026
Clinical validation
Clinical-trial records
Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple SclerosisNCT07111637 · Mentioned · RECRUITING
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple SclerosisNCT05949580 · Sponsor · SUSPENDED
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.NCT06280755 · Sponsor · RECRUITING
Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center StudyNCT07032246 · Sponsor · ENROLLING BY INVITATION
Remote MS Care in AntwerpNCT06179758 · Sponsor · ACTIVE NOT RECRUITING
The Impact of Traumatic Brain Injury in the ElderlyNCT04070092 · Mentioned · SUSPENDED
Regulatory
Regulatory records
icobrain ariaK240712 · 510k · Nov 7, 2024
icobrain-ctpK192962 · 510k · Feb 28, 2020
IcobrainK192130 · 510k · Dec 13, 2019
icobrainK181939 · 510k · Nov 6, 2018
icobrainK161148 · 510k · Aug 9, 2016
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
150% increased detection of disease activity in MS
Van Hecke et al., 2021
35% increase in radiological reading consistency
Van Hecke et al., 2021
2.5x faster detection of treatment failure
Sima et al., 2021
40% increase in radiological reading speed
Van Hecke et al., 2021
68% outcome improvement when employing icobrain vs drugs alone
Clinical evidence
Clinical research sites (Sima et al., 2021)
Multiple sclerosis treatment failure detection
2.5x faster detection of treatment failure
Multiple clinical sites (Van Hecke et al., 2021)
Multiple sclerosis disease activity detection and radiological reading efficiency
150% increased detection of disease activity in MS, 35% increase in radiological reading consistency, 40% increase in radiological reading speed
Clinical study participants
Multiple sclerosis treatment outcomes with icobrain vs drugs alone
68% outcome improvement when employing icobrain vs drugs alone
Shields Healthcare
Multiple sclerosis patient monitoring and detection of subtle changes over time
Improved detection of subtle changes in MS patients that may be missed without icobrain
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Joseph Fritz
President of the American Society of Neuroimaging
Tiron Pechet
Assistant Medical Director at Shields Healthcare
06 · Company updates
Updates from Icometrix
Recent articles published on Icometrix's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.